RBC Capital lowered the firm’s price target on Editas Medicine (EDIT) to $5 from $8 and keeps a Sector Perform rating on the shares. The firm sees this as an incremental quarter following the strategic pivot recently announced. Recall, Editas is now planning to partner/out-license the lead asset for SCD/BT and focus on the in vivo pipeline. Overall, RBC thinks partnering SCD/BT is the right strategic decision in the context of a slow uptake so far for the class, but remains on the sideline awaiting further progress on the in vivo pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDIT:
- Raymond James downgrades Editas on extended development timelines
- Editas Medicine downgraded to Market Perform from Outperform at Raymond James
- Editas Medicine reports Q3 EPS (75c), consensus (75c)
- Is EDIT a Buy, Before Earnings?
- Editas Medicine price target lowered to $9 from $27 at Wells Fargo
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
